News and Information_Guizhou Sinorda Pharmaceutical

Guizhou Sinorda Pharmaceutical Co., Ltd.

导航

Home
About
Product
- Product Center
- R&D pipeline
Platform
Blog
Talent
Contact
- Contact Information
- Online message

language

Home page

Sinorda Pharmaceutical and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

Category:

Company News

Time:2026-01-29 08:54

SHANGHAI, Jan. 29, 2026–Sinorda Pharmaceutical, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune diseases, today announced it has entered into a strategic collaboration agreement with WuXi Biologics (2269.HK). The partnership is specifically designed to accelerate the preclinical pharmacology studies and clinical manufacturing of SND006, Sinorda’s independently developed, novel bispecific antibody.

China-developed Innovative Drug "Linaprazan Glurate Capsules" Launches Nationwide with First Batch Shipment, Offering New Option for Patients with Reflux Esophagitis

Category:

Company News

Time:2026-01-05 17:33

On January 5, 2026, the first batch of Linaprazan Glurate Capsules (trade name: Xinlian®), a Class 1 innovative drug independently developed by Sinorda Biotechnology , was shipped for nationwide launch. This milestone marks the official clinical application of the world’s first Potassium-Competitive Acid Blocker (P-CAB) with an ester bond structure, bringing a brand-new treatment option to domestic patients suffering from reflux esophagitis.

Sinorda and HuaDong Pharma Enter into Commercialization Partnership for Linaprazan Glurate, a novel gastric acid inhibitor

Category:

Company News

Time:2025-12-10 18:28

Guiyang, China – December 7 – Guizhou Sinorda Biotech Co., Ltd., its wholly-owned subsidiary Shanghai Sinorda Medicine Tech. Co., Ltd., and Jiangsu Sinorda Biopharma Co., Ltd. (collectively, "Sinorda") announced that has entered into an exclusive commercialization agreement with Huadong Medicine (Hangzhou) Co., Ltd., which is wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZSE: 000963, "HuaDong Pharma") , for Mainland China for Sinorda's product Linaprazan Glurate Capsules and other dosage forms.

The Phase III clinical study of Linaprazan glurate—the National Investigators' Meeting—was held in Hangzhou, bringing together experts to collaboratively explore innovative treatment strategies for duodenal ulcers and Helicobacter pylori eradication.

Category:

Company News

Time:2025-11-08 13:38

On November 8, 2025, in Hangzhou—The national investigator meeting for the two Phase III clinical trials of "Linaprazan glurate (X842) Capsules," hosted by Shanghai Sinorda Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Sinorda) and co-organized by Anhui CTSMED Pharmaceutical Technology Co., Ltd. (hereinafter referred to as CTSMED), was successfully held in Hangzhou.

The 2025 Nobel Prize in Physiology or Medicine Announced

Category:

Industry News

Time:2025-10-06 13:56

On October 6, local time, Sweden's Karolinska Institute announced that the 2025 Nobel Prize in Physiology or Medicine will be awarded to scientists Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi, in recognition of their groundbreaking research on peripheral immune tolerance.

Sinorda Pharmaceutical Named to the "2025 China's Top 101 Innovative Pharmaceutical Companies" List

Category:

Company News

Time:2025-08-01 00:00

Sinorda Pharmaceutical Named Among "Top 101 Innovative Chinese Pharmaceutical Companies 2025"

Sinorda Pharmaceutical Wins Three Awards in the "Top 50 Biotech Innovators of the Greater Bay Area" at the 7th Edition

Category:

Company News

Time:2024-12-26 00:00

Sinorda Pharmaceutical has been honored with the titles of "2024 Investment-Value Enterprise" and "Pioneer Enterprise," while Dr. Hu Pingsheng, Chairman of the company, was awarded the prestigious "2024 Scientist of the Year" prize. IMG_258 IMG_257 IMG_256 Since its establishment in 2010, Sinorda Pharma has remained steadfastly focused on developing innovative drugs in the fields of gastrointestinal diseases and tumor immunotherapy. Leveraging its comprehensive biopharmaceutical R&D capabilities, the company continues to drive technological innovation and breakthroughs. Currently, the company’s globally innovative drug, linagliptin succinate, has successfully obtained the *Drug Registration Certificate* (National Drug Approval Number H20240042), and Sinorda is actively pursuing licensing agreements in several Asian countries. In addition, other pipeline products currently in clinical stages also demonstrate remarkable innovation and originality, addressing unmet medical needs and promising to bring significant benefits to more patients. This year’s selection process involved rigorous screening from over 1,000 companies, ultimately identifying 50 enterprises recognized for their exceptional potential and strength. The organizers evaluated each company comprehensively and thoroughly, considering multiple dimensions such as innovative technologies, market applications, and capital investment—alongside factors like core product development, service quality enhancement, R&D team building, technology patent acquisition, and corporate financial management. This multi-faceted assessment aims to uncover future unicorns in the biotech sector and propel the industry toward deeper, more sustainable growth. Against this backdrop, Sinorda Pharma has earned recognition in this prestigious selection due to its deep-rooted commitment to biotechnology and relentless pursuit of innovation. This achievement not only acknowledges the company’s past efforts but also underscores the high expectations placed on Sinorda Pharma to continue leading industry advancements and shaping emerging trends. Moving forward, Sinorda Pharma will remain dedicated to a pragmatic and innovative growth strategy, ramping up R&D investments, deepening technological breakthroughs, and striving to make even greater contributions to human health and well-being.

Sinorda Pharmaceutical Receives National Recognition as a High-Tech Enterprise

Category:

Company News

Time:2024-12-25 00:00

Sinorda Pharmaceutical Granted Recognition as a "National High-Tech Enterprise"

The next-generation P-CAB drug, "Linaprazan Glurate Capsules," has been approved for market launch.

Category:

Company News

Time:2024-12-03 00:00

On December 3, 2024, Shanghai Sinorda Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Guizhou Sinorda Pharmaceutical Co., Ltd. (hereinafter referred to as "Sinorda"), received the Drug Registration Certificate from the National Medical Products Administration for Linaprazan Glurate Capsules, a Class 1 new chemical drug approved for the treatment of reflux esophagitis.

Sinorda Pharmaceutical attends the 4th DJSeedin Innovation & Collaboration Summit

Category:

Company News

Time:2024-05-15 09:32

Sinorda Pharmaceutical attends the 4th DJSeedin Innovation & Collaboration Summit

< 1 2 > proceed page

Email: info1@sinorda.com

Zip code: 550018

Address: Guizhou Province Guiyang City National High-tech Zone West R & D Base

Consultation Hotline

0851-84847104

Business license

Label | Website construction: www.300.cn-GuiYang